Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Patent
1992-09-14
1994-09-20
Kepplinger, Esther L.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
435 5, 4351723, 4352351, 4353201, 935 32, 935 65, 4242241, 4242321, A61K 3112
Patent
active
053487419
ABSTRACT:
A plasmid vector has been constructed for producing unique vaccinia virus recombinant expressing the gene for rabiesvirus glycoprotein in cells. The recombinant induces production of glycoprotein in substantial amounts for immunization against rabies. Such recombinant could be applied for the production of anti-rabies vaccine and of G antigen antibody and related immunological reagents for research or diagnostic purposes.
REFERENCES:
patent: 4603112 (1986-07-01), Paoletti et al.
patent: 4631191 (1986-12-01), Dale et al.
patent: 4652629 (1987-03-01), Patrick et al.
patent: 4719177 (1988-01-01), Baltimore et al.
patent: 5017487 (1991-05-01), Stunnenberg et al.
Davis, et al., Microbiology , 2nd ed., Harper & Row, Hagerstown, Md., pp. 1258-1261 (1973).
Esposito, et al., Virus Genes 1:1,7-21, 1987.
Mackett, et al., DNA Cloning 2: 191-211, 1985.
Smith, et al., Laboratory Techniques in Rabies Appendix 5 pp. 354-357 1973.
Thomas, et al., Archives of Virology 49:217-227, 1975.
Parsons, et al., Virology 161:45-53, 1987.
Rosel, et al., Journal of Virology , 60:436-449, 1986.
Weir, et al., Journal of Virology 61:75-80, 1987.
Cochran, et al., Journal of Virology ,54:30-37, 1985.
Coupar et al, Eur. J. Immunol., vol. 16, pp. 1479-1487 (1986).
Baer, et al, American Journal of Epidemiology 93:487-490 1971.
World Health Organization Technical Report Series 709:57-62, 1984.
Lodmell et al, Journal of Virology, vol. 65, No. 6, pp. 3400-3405 (1991).
Sumner et al, Virology, vol. 183, pp. 703-710 (1991).
Lafon et al, J. Gen. Virol., vol. 68, pp. 3113-3123 (1987).
Dietzshold et al, Proc. Natl. Acad. Sci. USA, vol. 84 (24), pp. 9165-9169 (1987).
Pearson et al, Virology, vol. 180 (2), pp. 561-566 (1991).
Yaye F. Hermans, Bacteriological Proceedings V12, pg. 117, 1964.
Alexander, et al., Journal of Wildlife Diseases 8:119-126, 1972.
Esposito, et al., Virology 143:230-251, 1985.
E. Krag Andersen Proc. Symposium or Smallpox , 53-64, 1969.
Gezondheidstraad, et al. Symp. Series Immunbiol. 19:235-242, 1972.
Kieny, et al., (1984) Nature 312:163-166 "Expression of Rabies Virus Glycoprotein from a Recombinant Vaccinia Virus".
Wiktor, et al, (1984) Proc. Natl. Acad. Sci. USA 81:7194-7198 "Protection from rabies by a Vaccinia Virus Recombinant Containing the Rabies Virus Glycoprotein Gene".
Yelverton, et al, (1983) Science 219:614-620 "Virus Glycoprotein Analogs: Biosynthesis in Escherichia coli".
Abstract #86-01678 of EPO 117657.
Brechling Kathleen
Esposito Joseph J.
Moss Bernard
Kepplinger Esther L.
The United States of America as represented by the Department of
Wortman Donna C.
LandOfFree
Vector for recombinant poxvirus expressing rabies virus glycopro does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vector for recombinant poxvirus expressing rabies virus glycopro, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vector for recombinant poxvirus expressing rabies virus glycopro will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2429673